Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples
Abstract:
This work describes the human papillomavirus (HPV) prevalence and the HPV type distribution in a large series of vaginal intraepithelial neoplasia (VAIN) grades 2/3 and vaginal cancer worldwide. Methods We analysed 189 VAIN 2/3 and 408 invasive vaginal cancer cases collected from 31 countries from 1986 to 2011. After histopathological evaluation of sectioned formalin-fixed paraffin-embedded samples, HPV DNA detection and typing was performed using the SPF-10/DNA enzyme immunoassay (DEIA)/LiPA25 system (version 1). A subset of 146 vaginal cancers was tested for p16INK4a expression, a cellular surrogate marker for HPV transformation. Prevalence ratios were estimated using multivariate Poisson regression with robust variance. Results HPV DNA was detected in 74% (95% confidence interval (CI): 70-78%) of invasive cancers and in 96% (95% CI: 92-98%) of VAIN 2/3. Among cancers, the highest detection rates were observed in warty-basaloid subtype of squamous cell carcinomas, and in younger ages. Concerning the type-specific distribution, HPV16 was the most frequently type detected in both precancerous and cancerous lesions (59%). p16INK4a overexpression was found in 87% of HPV DNA positive vaginal cancer cases. Conclusions HPV was identified in a large proportion of invasive vaginal cancers and in almost all VAIN 2/3. HPV16 was the most common type detected. A large impact in the reduction of the burden of vaginal neoplastic lesions is expected among vaccinated cohorts.
Año de publicación:
2014
Keywords:
- Keywords Vaginal cancer
- human papillomavirus
- Vaccine
- Vaginal intraepithelial neoplasia
Fuente:
![scopus](/_next/image?url=%2Fscopus.png&w=128&q=75)
Tipo de documento:
Article
Estado:
Acceso restringido
Áreas de conocimiento:
- Cáncer
- Infección
Áreas temáticas:
- Enfermedades
Contribuidores:
![Quint W.G.V.](/autoricon.png)
![Saunier M.](/autoricon.png)
![Clavel C.](/autoricon.png)
![Muñoz N.](/autoricon.png)
![Sica A.R.](/autoricon.png)
![Bravo I.G.](/autoricon.png)
![Alejo M.](/autoricon.png)
![Guimerà N.](/autoricon.png)
![Klaustermeier J.](/autoricon.png)
![Maldonado P.](/autoricon.png)
![Cross P.](/autoricon.png)
![Wain V.](/autoricon.png)
![Leopoldo Tinoco](/autoricon.png)
![Jach R.](/autoricon.png)
![Clavero O.](/autoricon.png)
![Xavier Bosch F.](/autoricon.png)
![Salmeron J.](/autoricon.png)
![Shin H.R.](/autoricon.png)
![Petry K.U.](/autoricon.png)
![Carrilho C.](/autoricon.png)
![Molina C.](/autoricon.png)
![Quirós B.](/autoricon.png)
![Geraets D.T.](/autoricon.png)
![Lombardi L.E.](/autoricon.png)
![Kitchener H.](/autoricon.png)
![Pawlita M.](/autoricon.png)
![Murillo R.](/autoricon.png)
![De Sanjosé S.](/autoricon.png)
![Nowakowski A.M.](/autoricon.png)
![Alemany L.](/autoricon.png)
![Vidal A.](/autoricon.png)
![Mandys V.](/autoricon.png)
![Alvarado-Cabrero I.](/autoricon.png)
![Joura E.A.](/autoricon.png)
![Magaña-León C.](/autoricon.png)
![Bergeron C.](/autoricon.png)